Can gene editing drive out HIV and hepatitis viruses from inside cells?
By Cormac Sheridan,
Nature Biotechnology
| 10. 30. 2023
A gene-editing therapy based on CRISPR–Cas9 designed to eliminate HIV-1 infection has rekindled hopes among scientists that it may be possible to eradicate the virus and cure the infection. In an in vivo editing study in non-human primates conducted by scientists from Temple University and Excision BioTherapeutics, a single dose of a CRIPSR therapy excised the simian immunodeficiency virus (closely related to HIV-1) from the DNA of infected animals with no observable off-target effects or other safety problems. The equivalent human therapy, EBT-101, is undergoing a phase 1/2 clinical trial in people infected with HIV-1.
This CRISPR therapy is part of a wave of sophisticated genetic approaches targeting difficult-to-treat chronic infections (Table 1). In addition to gene editing, therapies, including antisense oligonucleotides, short interfering RNA (siRNA), gene therapy, therapeutic vaccines and chimeric antigen receptor (CAR)-T cell therapies, are being brought to bear on a range of pathogens, but most prominently on HIV-1 and chronic hepatitis B virus (HBV) infection.
Once a person is infected and after the acute stage resolves, these viruses can persist indefinitely — in CD4 T...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...